



Accessibility Statement

FamGenix is committed to providing a website that is accessible to the widest possible audience, regardless of technology or ability. We are actively working to increase the accessibility and usability of our website and, in doing so, adhere to many of the available standards and guidelines.

Conformance Status

The **Web Content Accessibility Guidelines (WCAG)** defines requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA. Our website is partially conformant with **WCAG 2.1 Level A**. Partial conformance means that some parts of the content do not yet fully conform to the accessibility standard. We are actively working to remediate these issues and improve the user experience for everyone.

Known Accessibility Limitations

We are aware of the following known limitations on our password-protected website. Please contact us if you encounter an issue not listed below.

Provider Portal:

- **Some buttons do not have an accessible name:** Some buttons such as the home and help buttons are icons without a discernible name. We are working to add names to these buttons.
- **Buttons do not have sufficient contrast ratio:** Some buttons do not have sufficient contrast ratio to be easy to read for all users.

Patient Portal:

- **Background and foreground color contrast ratio:** Some text such as the field labels on log in do not have sufficient contrast to the background to make them easily readable by all users.
- **Not all form elements have associated labels:** Some form elements are missing labels that will ensure they are announced properly by assistive technologies.



Feedback and Support

We welcome your feedback on the accessibility of our website. If you encounter any accessibility barriers, please don't hesitate to contact us.

- **Email:** info@famgenix.com
- **Phone:** (833) 221-6900
- **Contact Form:** <https://famhis.atlassian.net/servicedesk/customer/portals>

Formal Approval

This statement was approved on September 3, 2025 by FamGenix.

Date of Last Review

This statement was last reviewed on September 3, 2025.